Editor’s note: This is a developing news story. Please check back soon for updates.
Viridian Therapeutics received breakthrough therapy designation from the FDA for veligrotug for the treatment of thyroid eye disease, according to a press release.
Veligrotug, also known as veli and VRDN-001, is an anti-insulin-like growth factor-1 receptor antibody delivered intravenously for thyroid eye disease (TED). Veli met the primary and secondary endpoints in the THRIVE and THRIVE-2 pivotal phase 3 clinical trials and demonstrated rapid reduction and resolution of diplopia in both trials, according